Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly and Co Patrik Jonsson; Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USA; Eli Lilly and Co Anne White; Executive Vice President, President - Lilly ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Lilly didn’t mince words about what sparked that growth, pointing to an impressive 60% sales leap for its type 2 diabetes blockbuster Mounjaro, which brought home $3.5 billion over the last ...

The pharmaceutical company is expected to benefit from blockbuster products like ... Alzheimer's disease in July 2024. Eli Lilly's late-stage pipeline, led by oral obesity and diabetes drug ...

We are maintaining Eli Lilly’s Uncertainty Rating of High based on a high variable outcome for several key drug launches. Diabetes and ... sell different types of products and services to ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...